ECP
EFTRW

Empyrean Capital Partners’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Empyrean Capital Partners’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-279,502
Closed -$170K – 182
2021
Q1 		$170K Buy
+279,502
New +$270K ﹤0.01% 158

Other funds holding EFTRW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Empyrean Capital Partners's EFTRW Position: Q2 2021 in Review

Empyrean Capital Partners sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q2 2021, closing a stake of 279,502 shares — an estimated $170K sold.

Empyrean Capital Partners first reported a position in EFTRW in Q1 2021 and held it in 1 quarter. The position peaked at $170K in Q1 2021. 38 funds tracked by Wall St. Rank hold EFTRW as of Q2 2021.

  • Empyrean Capital Partners reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Empyrean Capital Partners sold 279,502 eFFECTOR Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $170K.
  • Empyrean Capital Partners first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Empyrean Capital Partners's eFFECTOR Therapeutics, Inc. Warrant position peaked at $170K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q2 2021.

Based on Empyrean Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.